Medically reviewed by Dr. Rao Khurram Ayoub, RPh, PhD (Pharmaceutics)
Updated on
CDAI Clinical Calculator
Calculate real-time Clinical Disease Activity Index levels using standard point-of-care metric sets without laboratory values.
User Guide: Executing a CDAI Assessment
To perform a Clinical Disease Activity Index (CDAI) calculation, follow these four structured steps during or immediately following a physical joint examination.
Count Tender Joints (TJC28)
Palpate the 28 standard joints — shoulders, elbows, wrists, metacarpophalangeal, proximal interphalangeal, and knees. Record the total number of joints causing pain or tenderness upon pressure. Range: 0–28
Count Swollen Joints (SJC28)
Inspect and palpate the exact same 28 joints for visible or fluctuant soft-tissue swelling or fluid accumulation. Record the total. Range: 0–28
Record Patient Global Assessment (PGA)
Ask the patient to estimate their overall arthritis disease activity over the past 24 hours on a visual analog scale from 0.0 (feeling entirely well) to 10.0 (severe disease activity). Range: 0.0–10.0
Record Evaluator Global Assessment (EGA)
As the clinician, score the patient's current global disease activity from 0.0 to 10.0 based on your physical findings and clinical impression. Range: 0.0–10.0
The tool aggregates these metrics into a raw numerical score ranging from 0.0 to 76.0.
Interpreting the Results: Clinical Tiers & Disease Management
The resulting numerical value maps directly to verified clinical decision-making paths established under modern "Treat-to-Target" guidelines.
Remission
≤ 2.8Absolute control of systemic inflammation.
Maintain current disease-modifying antirheumatic drug (DMARD) therapies. If remission is sustained for more than six consecutive months, clinicians can cautiously initiate a structured, stepwise biological or conventional therapeutic tapering protocol.
Low Disease Activity
2.9 – 10.0Mild residual joint inflammation with minimal progression risks.
Acceptable as a pragmatic target in long-standing or complex chronic cases where aggressive escalation poses prohibitive safety risks.
Moderate Disease Activity
10.1 – 22.0Active, ongoing synovitis that threatens physical function and joint architecture.
Prompts a formal therapeutic re-evaluation. Clinicians typically scale up conventional synthetic DMARD doses, optimize bioavailability (such as shifting from oral to subcutaneous methotrexate), or introduce targeted biologic or synthetic agents.
High Disease Activity
> 22.0Uncontrolled, destructive systemic inflammation.
Mandates immediate, aggressive pharmacological escalation. Leaving a patient in this tier risks rapid, irreversible radiographic bone erosion, permanent joint deformities, and systemic extra-articular complications.
Why the CDAI is trusted for tracking RA outcomes
In clinical tracking, using a laboratory-independent score like the CDAI is heavily supported by modern data. It prevents diagnostic delays caused by waiting for acute-phase reactant blood tests.
Assess disease activity at the bedside — no CRP or ESR results required.
Enables real-time treatment escalation without diagnostic delay.
Equipotent Corticosteroid Converter
RA management frequently involves corticosteroid therapy — often in combination with DMARDs during flares. When switching between prednisone, methylprednisolone, dexamethasone, or hydrocortisone, accurate dose conversion is critical to prevent under-treatment or steroid toxicity.
Open the equipotent corticosteroid converter →